COMMUNIQUÉS West-GlobeNewswire

Sienna Senior Living Inc. Reports Strong Second Quarter 2024 Financial Results and Announces Publication of 2023-2024 ESG Report

08/08/2024 - 22:15

MARKHAM, Ontario, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2024. The [...]

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08/08/2024 - 22:10

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM [...]

TerrAscend Reports Second Quarter 2024 Financial Results

08/08/2024 - 22:10

Net Revenue of $77.5 million, an increase of 7.5% year-over-year Cash Flow from continuing operations of $13.1 million and Free Cash Flow 1 of $11.7 million #1 market share position in New Jersey throughout first half [...]

Anika Reports Second Quarter 2024 Financial Results

08/08/2024 - 22:05

Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand [...]

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

08/08/2024 - 22:05

On-track for trem-cel + Mylotarg™ and VCAR33 ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering [...]

Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter

08/08/2024 - 22:05

Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago “Fair Deal Agreement” recurring revenue [...]

Aligos Therapeutics Strengthens Board with Two New Independent Directors

08/08/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to [...]

23andMe Reports First Quarter Fiscal 2025 Financial Results

08/08/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal [...]

Kura Oncology Reports Second Quarter 2024 Financial Results

08/08/2024 - 22:05

– Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – – Data from 100 patients [...]

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

08/08/2024 - 22:05

FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

08/08/2024 - 22:05

CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]

Cytek Biosciences to Participate in Upcoming Investor Conferences

08/08/2024 - 22:05

FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]

Trevena Announces Reverse Stock Split

08/08/2024 - 22:05

CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system [...]

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

08/08/2024 - 22:05

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: [...]

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

08/08/2024 - 22:05

Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with [...]

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

08/08/2024 - 22:05

Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for SC291 in B-cell mediated [...]

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08/08/2024 - 22:05

Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2- [...]

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

08/08/2024 - 22:05

- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade [...]

scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

08/08/2024 - 22:05

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and [...]